Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding

Seth A. Stabinsky, Mark Einstein, James L. Breen

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Menorrhagia (excessive uterine bleeding) affects some 20 percent of the women of reproductive age worldwide. The following review describes known and theorized etiologies of the disorder, followed by a discussion of treatment options that are currently in use as well as those on the horizon. There is much interest internationally in decreasing hysterectomy rates, particularly for those women with abnormal bleeding and anatomically normal uteri. It is these women who are the focus of this paper. Pharmacotherapy and surgery are the mainstay treatments for such patients with menorrhagia secondary to dysfunctional uterine bleeding. Most commonly, hormonal and nonhormonal medications are followed by dilatation and curettage, and ultimately, in many cases, hysterectomy. Endometrial ablation techniques have been evolving since the 1980s in response to the need for an efficacious, safer, and more cost- effective alternatives to hysterectomy. Hysteroscopic ablation achieves these goals but is difficult technically and requires significant additional training even for otherwise skilled and experienced gynecologists. The current decade has seen the development of many innovative approaches to performing endometrial ablation. These methods are intended to be much simpler to perform with less risk than electrosurgical or laser endometrial ablation. The final section of this article presents the published data to date on these new technologies, which should (in their refined state) revolutionize the treatment of menorrhagia secondary to dysfunctional uterine bleeding.

Original languageEnglish (US)
Pages (from-to)61-72
Number of pages12
JournalObstetrical and Gynecological Survey
Volume54
Issue number1
DOIs
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Endometrial Ablation Techniques
Menorrhagia
Metrorrhagia
Hysterectomy
Dilatation and Curettage
Uterine Hemorrhage
Laser Therapy
Uterus
Therapeutics
Hemorrhage
Technology
Costs and Cost Analysis
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. / Stabinsky, Seth A.; Einstein, Mark; Breen, James L.

In: Obstetrical and Gynecological Survey, Vol. 54, No. 1, 01.1999, p. 61-72.

Research output: Contribution to journalArticle

Stabinsky, Seth A. ; Einstein, Mark ; Breen, James L. / Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. In: Obstetrical and Gynecological Survey. 1999 ; Vol. 54, No. 1. pp. 61-72.
@article{93c8ea7119624ba8b775ea964e5fa27b,
title = "Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding",
abstract = "Menorrhagia (excessive uterine bleeding) affects some 20 percent of the women of reproductive age worldwide. The following review describes known and theorized etiologies of the disorder, followed by a discussion of treatment options that are currently in use as well as those on the horizon. There is much interest internationally in decreasing hysterectomy rates, particularly for those women with abnormal bleeding and anatomically normal uteri. It is these women who are the focus of this paper. Pharmacotherapy and surgery are the mainstay treatments for such patients with menorrhagia secondary to dysfunctional uterine bleeding. Most commonly, hormonal and nonhormonal medications are followed by dilatation and curettage, and ultimately, in many cases, hysterectomy. Endometrial ablation techniques have been evolving since the 1980s in response to the need for an efficacious, safer, and more cost- effective alternatives to hysterectomy. Hysteroscopic ablation achieves these goals but is difficult technically and requires significant additional training even for otherwise skilled and experienced gynecologists. The current decade has seen the development of many innovative approaches to performing endometrial ablation. These methods are intended to be much simpler to perform with less risk than electrosurgical or laser endometrial ablation. The final section of this article presents the published data to date on these new technologies, which should (in their refined state) revolutionize the treatment of menorrhagia secondary to dysfunctional uterine bleeding.",
author = "Stabinsky, {Seth A.} and Mark Einstein and Breen, {James L.}",
year = "1999",
month = "1",
doi = "10.1097/00006254-199901000-00025",
language = "English (US)",
volume = "54",
pages = "61--72",
journal = "Obstetrical and Gynecological Survey",
issn = "0029-7828",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding

AU - Stabinsky, Seth A.

AU - Einstein, Mark

AU - Breen, James L.

PY - 1999/1

Y1 - 1999/1

N2 - Menorrhagia (excessive uterine bleeding) affects some 20 percent of the women of reproductive age worldwide. The following review describes known and theorized etiologies of the disorder, followed by a discussion of treatment options that are currently in use as well as those on the horizon. There is much interest internationally in decreasing hysterectomy rates, particularly for those women with abnormal bleeding and anatomically normal uteri. It is these women who are the focus of this paper. Pharmacotherapy and surgery are the mainstay treatments for such patients with menorrhagia secondary to dysfunctional uterine bleeding. Most commonly, hormonal and nonhormonal medications are followed by dilatation and curettage, and ultimately, in many cases, hysterectomy. Endometrial ablation techniques have been evolving since the 1980s in response to the need for an efficacious, safer, and more cost- effective alternatives to hysterectomy. Hysteroscopic ablation achieves these goals but is difficult technically and requires significant additional training even for otherwise skilled and experienced gynecologists. The current decade has seen the development of many innovative approaches to performing endometrial ablation. These methods are intended to be much simpler to perform with less risk than electrosurgical or laser endometrial ablation. The final section of this article presents the published data to date on these new technologies, which should (in their refined state) revolutionize the treatment of menorrhagia secondary to dysfunctional uterine bleeding.

AB - Menorrhagia (excessive uterine bleeding) affects some 20 percent of the women of reproductive age worldwide. The following review describes known and theorized etiologies of the disorder, followed by a discussion of treatment options that are currently in use as well as those on the horizon. There is much interest internationally in decreasing hysterectomy rates, particularly for those women with abnormal bleeding and anatomically normal uteri. It is these women who are the focus of this paper. Pharmacotherapy and surgery are the mainstay treatments for such patients with menorrhagia secondary to dysfunctional uterine bleeding. Most commonly, hormonal and nonhormonal medications are followed by dilatation and curettage, and ultimately, in many cases, hysterectomy. Endometrial ablation techniques have been evolving since the 1980s in response to the need for an efficacious, safer, and more cost- effective alternatives to hysterectomy. Hysteroscopic ablation achieves these goals but is difficult technically and requires significant additional training even for otherwise skilled and experienced gynecologists. The current decade has seen the development of many innovative approaches to performing endometrial ablation. These methods are intended to be much simpler to perform with less risk than electrosurgical or laser endometrial ablation. The final section of this article presents the published data to date on these new technologies, which should (in their refined state) revolutionize the treatment of menorrhagia secondary to dysfunctional uterine bleeding.

UR - http://www.scopus.com/inward/record.url?scp=0032894427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032894427&partnerID=8YFLogxK

U2 - 10.1097/00006254-199901000-00025

DO - 10.1097/00006254-199901000-00025

M3 - Article

VL - 54

SP - 61

EP - 72

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

SN - 0029-7828

IS - 1

ER -